Myovant Sciences Ltd. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 32 rows in 2019. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-08-26: Reporting owner Sablich Kim; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2019-08-26: Reporting owner Sablich Kim; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-08-26: Reporting owner Sablich Kim; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2019-08-26: Reporting owner Sablich Kim; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-08-26 | Sablich Kim Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −133,500 0 owned after | $17.28 exercise price | 2019-08-27 | |
| 2019-08-26 | Sablich Kim Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +133,500 133,500 owned after | $7.78 exercise price | 2019-08-27 | |
| 2019-08-26 | Sablich Kim Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −66,130 0 owned after | $24.44 exercise price | 2019-08-27 | |
| 2019-08-26 | Sablich Kim Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +66,130 66,130 owned after | $7.78 exercise price | 2019-08-27 | |
| 2019-08-26 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −310,000 0 owned after | $11.30 exercise price | 2019-08-27 | |
| 2019-08-26 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +310,000 310,000 owned after | $7.78 exercise price | 2019-08-27 | |
| 2019-08-26 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −87,050 0 owned after | $21.87 exercise price | 2019-08-27 | |
| 2019-08-26 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +87,050 87,050 owned after | $7.78 exercise price | 2019-08-27 | |
| 2019-08-26 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −152,110 0 owned after | $24.44 exercise price | 2019-08-27 | |
| 2019-08-26 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +152,110 152,110 owned after | $7.78 exercise price | 2019-08-27 | |
| 2019-08-26 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −200,000 0 owned after | $12.68 exercise price | 2019-08-27 | |
| 2019-08-26 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $7.78 exercise price | 2019-08-27 | |
| 2019-08-26 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −114,690 0 owned after | $21.87 exercise price | 2019-08-27 | |
| 2019-08-26 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +114,690 114,690 owned after | $7.78 exercise price | 2019-08-27 | |
| 2019-08-26 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −132,270 0 owned after | $24.44 exercise price | 2019-08-27 | |
| 2019-08-26 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +132,270 132,270 owned after | $7.78 exercise price | 2019-08-27 | |
| 2019-08-26 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −260,000 0 owned after | $10.60 exercise price | 2019-08-27 | |
| 2019-08-26 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +260,000 260,000 owned after | $7.78 exercise price | 2019-08-27 | |
| 2019-08-26 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −87,050 0 owned after | $21.87 exercise price | 2019-08-27 | |
| 2019-08-26 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +87,050 87,050 owned after | $7.78 exercise price | 2019-08-27 | |
| 2019-08-26 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −66,130 0 owned after | $24.44 exercise price | 2019-08-27 | |
| 2019-08-26 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +66,130 66,130 owned after | $7.78 exercise price | 2019-08-27 | |
| 2019-08-23 | Torti Frank Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +58,608 58,608 owned after | $7.65 exercise price | 2019-08-27 | |
| 2019-08-23 | Sebelius Kathleen Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +58,608 58,608 owned after | $7.65 exercise price | 2019-08-27 | |
| 2019-08-23 | POTTER MYRTLE S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +58,608 58,608 owned after | $7.65 exercise price | 2019-08-27 | |
| 2019-08-23 | GUINAN MARK Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +58,608 58,608 owned after | $7.65 exercise price | 2019-08-27 | |
| 2019-08-23 | Curran Terrie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +58,608 58,608 owned after | $7.65 exercise price | 2019-08-27 | |
| 2019-04-05 | Sablich Kim Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +66,130 66,130 owned after | $24.44 exercise price | 2019-04-09 | |
| 2019-04-05 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +152,110 152,110 owned after | $24.44 exercise price | 2019-04-09 | |
| 2019-04-05 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +66,130 66,130 owned after | $24.44 exercise price | 2019-04-09 | |
| 2019-04-05 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +132,270 132,270 owned after | $24.44 exercise price | 2019-04-09 | |
| 2019-04-05 | Seely Lynn Director, Officer (Principal Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +330,660 330,660 owned after | $24.44 exercise price | 2019-04-09 |